Next Article in Journal
Liver Fibrosis Assessment with Diffusion-Weighted Imaging: Value of Liver Apparent Diffusion Coefficient Normalization Using the Spleen as a Reference Organ
Previous Article in Journal
The HD-OCT Study May Be Useful in Searching for Markers of Preclinical Stage of Diabetic Retinopathy in Patients with Type 1 Diabetes
Open AccessReview

FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review

1
Department of Clinical Research, University of Southern Denmark, 5230 Odense, Denmark
2
Department of Nuclear Medicine, Odense University Hospital, 5000 Odense, Denmark
3
Department of Oncology, Odense University Hospital, 5000 Odense, Denmark
4
Centre for Personalized Response Monitoring in Oncology (PREMIO), 5000 Odense, Denmark
5
Centre for Innovative Medical Technology, Odense University Hospital, 5000 Odense, Denmark
*
Author to whom correspondence should be addressed.
Diagnostics 2019, 9(3), 106; https://doi.org/10.3390/diagnostics9030106
Received: 21 July 2019 / Revised: 16 August 2019 / Accepted: 23 August 2019 / Published: 27 August 2019
(This article belongs to the Section Medical Imaging)
18F-fluorodeoxyglucose positron emission tomography with integrated computed tomography (FDG-PET/CT) and contrast-enhanced computed tomography (CT) can be used for response evaluation in metastatic breast cancer (MBC). In this study, we aimed to review literature comparing the PET Response Criteria in Solid Tumors (PERCIST) with Response Evaluation Criteria in Solid Tumors (RECIST) in patients with MBC. We made a systematic search in Embase, PubMed/Medline, and Cochrane Library using a modified PICO model. The population was MBC patients and the intervention was PERCIST or RECIST. Quality assessment was performed using the QUADAS-2 checklist. A total of 1975 articles were identified. After screening by title/abstract, 78 articles were selected for further analysis of which 2 duplicates and 33 abstracts/out of focus articles were excluded. The remaining 43 articles provided useful information, but only one met the inclusion and none of the exclusion criteria. This was a retrospective study of 65 patients with MBC showing one-year progression-free survival for responders versus non-responders to be 59% vs. 27% (p = 0.2) by RECIST compared to 64% vs. 0% (p = 0.0001) by PERCIST. This systematic literature review identified a lack of studies comparing the use of RECIST (with CE-CT) and PERCIST (with FDG-PET/CT) for response evaluation in metastatic breast cancer. The available sparse literature suggests that PERCIST might be more appropriate than RECIST for predicting prognosis in patients with MBC. View Full-Text
Keywords: FDG-PET/CT; PERCIST; CE-CT; RECIST; response evaluation; metastatic breast cancer FDG-PET/CT; PERCIST; CE-CT; RECIST; response evaluation; metastatic breast cancer
Show Figures

Figure 1

MDPI and ACS Style

Helland, F.; Hallin Henriksen, M.; Gerke, O.; Vogsen, M.; Høilund-Carlsen, P.F.; Hildebrandt, M.G. FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review. Diagnostics 2019, 9, 106.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop